Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same
historically intransigent problem that has existed since the initial description of the disease in …

Amyotrophic lateral sclerosis (ALS) is one of the most rapidly progressive
neurodegenerative diseases of unknown cause. Riluzole is the only drug that slows disease …

Introduction: Numerous methods for motor unit number estimation (MUNE) have been
developed. The objective of this article is to summarize and compare the major methods and …

Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes
with different progression rates, varying degree of extra-motor involvement and divergent …

Background Amyotrophic lateral sclerosis (ALS) a highly heterogeneous neurodegenerative
condition. Accurate diagnostic, monitoring and prognostic biomarkers are urgently needed …

Development of effective treatments for amyotrophic lateral sclerosis (ALS) has been
hampered by disease heterogeneity, a limited understanding of underlying pathophysiology …

Our objective is to describe the results of a phase II/III, 12-months, double-blinded, single-
centre, randomized, parallel (1: 1), clinical trial performed to evaluate the efficacy and safety …

PURPOSE: To profile the detailed clinical features of sporadic amyotrophic lateral sclerosis
(ALS) on large-scale samples in Japan. METHODS: We assessed the clinical features of …

The progressive course of amyotrophic lateral sclerosis (ALS) results in an ever-changing
spectrum of the care needs of patients with ALS. Knowledge of prognostic factors for the …

Human genetics plays an increasingly important role in drug development and population
health. Here we review the history of human genetics in the context of accelerating the …